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In 2017, JAMA published a statistical analysis plan
(SAP) guidance document for randomised clinical trials
(RCTs). This guidance is part of the EQUATOR Net-
work of reporting resources and includes a checklist of
minimum items for reporting details of statistical ana-
lysis of RCTs [1]. While the clinical trial protocol should
describe the principal features of the statistical analysis,
a separate detailed SAP containing sufficient information
to support replication by an independent statistician
may be needed [2–4].
Given the influence of statistical decisions on trial con-
clusions, well-documented statistical conduct is essential
for transparency and reproducibility of the research.
Additionally, pre-specification is important to reduce the
occurrence of, and facilitate the detection of, bias par-
ticularly in relation to selective analysis and reporting [5,
6]. While guidance exists on the content of protocols [2]
and final reports for clinical trials [7], both of which re-
quire at a minimum a summary of the statistical ana-
lyses, there was until recently no guidance on SAP
content. Consequently, there is marked variation in the
level of detail provided to allow full replication of statis-
tical analysis. The development of guidance for the con-
tent of SAPs aims to reduce this variation and to
promote full and transparent reporting of pre-specified
analyses [1].
Trials therefore encourages the submission for publi-
cation of SAPs, which are in line with the guidance
document [1], in any of the following formats:
(i) A section directly integrated in the protocol being
submitted for publication (for uncomplicated RCTs
this might be sufficient);
(ii) An appendix within the protocol being submitted
for publication;
(iii)An addendum submitted subsequent to the published
protocol paper in Trials as a newly peer-reviewed up-
date and which subsequent to publication would be
treated much like an appendix to the protocol;
(iv)A separate stand-alone, fully published article, with
its own author list and DOI, referencing an already-
published protocol (in Trials or elsewhere).
These options underscore the importance of the publi-
cation of SAPs but also ensure that the reporting of
SAPs as separate publications is not made mandatory.
For many RCTs, the statistical analysis plan is likely to
be uncomplicated and feasibly be defined in full at the
time of writing the protocol. For more complex trials,
such as those with adaptive designs or those using new
methodologies, the development of the SAP might take
longer than that of the protocol. Trials is actively en-
couraging researchers to publish their SAPs in the for-
mat that fits the complexity of their analysis plan.
Whatever option is selected, all authors are encouraged
to use the SAP reporting guideline [1]. Both authors and
reviewers are therefore tasked with ensuring both
reporting according to the SAP reporting guideline [1]
as well as the SPIRIT guidance for the protocol as a
whole [2].
Different approaches to peer review are anticipated de-
pending on the style of submission and consist of the
following:
(i) If the SAP is submitted as part of the protocol, or
an appendix to the protocol, peer review of the SAP
will be undertaken in conjunction with review of
the protocol following current Trials guidance for
protocols which includes checking against the SAP
reporting standard [8].
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(ii) If the SAP is submitted as an addendum to an
already published protocol in Trials, authors will be
expected to verify and demonstrate reporting
against the SAP reporting guideline and the
submission will undergo review as deemed
appropriate by the handling editor and which might
consist of review by the editor only.
(iii) If the SAP is submitted as a separate publication,
the submission will undergo peer review (for those
that contain novel or more complicated statistical
analysis proposals this would include statistical
review) and the SAP would be checked against the
SAP reporting standard.
By allowing a number of approaches, Trials encour-
ages proportionate review. High-quality peer review has
to be balanced against the availability of the academic
community to serve as reviewers in times of increasing
demands. Thus, peer review might be treated somewhat
like a scarce resource. Mandating that every trial must
have a published protocol and a separate published SAP
may well be beyond the timely reviewing capacity of the
trial’s community and so should be reserved for those
trials for which the level of detail required in the SAP
cannot be incorporated into the protocol. Authors
should be mindful that these approaches do not distract
from relevant legislation and guidelines on when SAPs
should be competed.
Trials would thus like to encourage the early publica-
tion of SAPs and the use of the SAP guidance and check-
list for peer reviewing SAPs put forward for publication.
Full details on the submission process for the different
types of submissions, along with examples, are available
[8]. Regardless, we encourage journals to include the
protocol and SAP as online addenda to each peer
reviewed results paper they publish [9]. SAPs, like proto-
cols, are living documents: SAPs may need to be updated,
perhaps in response to new methods or emerging exter-
nal evidence. In these instances, amendments can be
made by (i) submitting an amendment as an update to ei-
ther the protocol paper or SAP paper, or (ii) document-
ing changes to the SAP as part of the published final
report (likely to be appropriate for minor changes), as per
CONSORT guidance for changes which occurred during
the trial [10]. Amendments should also be recorded on
the relevant clinical trials registration site and with other
relevant bodies as appropriate. Authors are requested to
ensure clarity when publishing the SAP within a protocol
as to whether it the preliminary or final version.
These different approaches to publication not only re-
flect differences in nature of complexity of SAPs but also
promote opportunities for statisticians to take lead
authorship positions. The approach endorsed by Trials
will allow appropriate reflection of the level of academic
credit that should be accredited to statisticians for their
role in planning of randomised trials. Trials also encour-
ages that funders support requests for publication costs
associated with this publication.
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